This work also illustrates that P53 inactivation in the hematopoietic cells endogenous JAK2V617F context is not sufficient to directly induce the transformation of MPN despite inducing a proliferative advantage over p53 WT cells in the short-term, but we can not definitively exclude such an effect in the long-term. The gene discussed is TP53; the disease is myeloproliferative neoplasm.